IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Biotechnology

Healthcare
$26.49 -1.45%

-$0.45 today

Market cap
$2.56B
Beta
-0.05
P/E (TTM)
-19.5
EPS (TTM)
-$1.58
52W Low $20.50High $39.28

Volume 1.45M

Average 1.44M

IDYA Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

IDEAYA Biosciences, Inc.NASDAQ: IDYA

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin at -1654.6%

Operating margin was -1654.6% in Q1 FY2026. On a trailing-twelve-month basis it was -81.4%, up 5066.4 pp year over year. Over 3 fiscal years it widened by 49.9 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 11 analysts of -893.7% for the fiscal year ending Dec 2026, down from -72.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-1654.6%-785.1 pp QoQ
Last fiscal yearDec 2025
-72.8%+4598.2 pp YoY
LTMMar 2026
-81.4%+5066.4 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+4598.2 pp-820.9 pp-5419.1 pp
3 years+49.9 pp-61.0 pp-110.9 pp
5 years+73.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-72.8%
Year-over-year change
+4598.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How IDYA compares with its peers on the latest reported figures

  • IDYA's LTM Mar 2026 operating margin of -81.4% is the 2nd highest of the 6 companies compared; the peer median is -286.2%.
  • Its year-over-year change of +5066.4 pp is the highest of 6, against a peer median of +360.6 pp.
  • Over three fiscal years its change of +49.9 pp compares with a peer median of +306.0 pp.
IDYA Competitors Peer median
Operating Margin for IDYA and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202641.3% +360.6 pp+135.8 pp
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-81.4% +5066.4 pp+49.9 pp
TNGXTango Therapeutics, Inc.FY2025-178.4% +167.7 pp+268.4 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-286.2% +128.2 pp+343.6 pp
VSTMVerastem, Inc.LTM Mar 2026-344.6% +966.2 pp+2259.3 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-503.2% +1496.5 pp—
RVMDRevolution Medicines, Inc.FY2025— ——
ERASErasca, Inc.FY2025— ——
COGTCogent Biosciences, Inc.FY2025— ——
Peer median (excluding IDYA) -286.2%+360.6 pp+306.0 pp

Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.94M50.93M23.39M7M218.71M
Cost of Revenue1.73M2.1M4.01M3.83M4.59M
Gross Profit26.22M48.83M19.38M3.17M214.12M
Gross Margin93.8%95.9%82.9%45.2%97.9%
Research & Development58.16M89.54M129.51M294.67M314.7M
Selling, General & Admin18.33M21.8M24.3M35.47M63.32M
Operating Expenses76.48M111.33M153.81M330.14M373.43M
Depreciation & Amortization1.73M2.1M4.01M3.83M4.59M
EBITDA(48.04M)(56.55M)(108.95M)(270.64M)(109.11M)
EBITDA Margin-171.9%-111.0%-465.9%-3866.3%-49.9%
Operating Income(50.27M)(62.5M)(134.43M)(326.98M)(159.31M)
Operating Margin-179.9%-122.7%-574.9%-4671.1%-72.8%
Interest Income506K3.85M21.47M52.5M45.62M
Interest Expense00000
Other Income / Expenses506K3.85M21.47M52.5M45.62M
Income Before Tax(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Pre-Tax Margin-178.1%-115.2%-483.0%-3921.1%-52.0%
Income Tax Expense00000
Net Income(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Net Margin-178.1%-115.2%-483.0%-3921.1%-52.0%
EPS (Basic)(1.41)(1.42)(1.96)(3.36)(1.28)
EPS (Diluted)(1.41)(1.42)(1.96)(3.36)(1.28)
Weighted Avg Shares35.25M41.44M57.52M81.68M88.49M
Weighted Avg Shares (Diluted)35.25M41.44M57.52M81.68M88.49M

IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Intrinsic Alpha fair value

Locked

Current Price

$26.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.